Loading
A phase 3 trial testing MRG002 in bladder & urothelial cancer, now recruiting.
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT05754853, led by Shanghai Miracogen, and recruiting on the registry. Official title: An Open-label, Randomised, Multi-centre, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors. Planned enrolment is 290 participants (estimated). The study started in 2023-04-06 and primary completion is expected in 2025-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Miracogen, MRG002.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/